Ex vivo-expanded CD4+ CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells

A Trenado, M Sudres, Q Tang, S Maury… - The Journal of …, 2006 - journals.aai.org
A Trenado, M Sudres, Q Tang, S Maury, F Charlotte, S Grégoire, M Bonyhadi, D Klatzmann
The Journal of Immunology, 2006journals.aai.org
Abstract CD4+ CD25+ immunoregulatory T cells (Tregs) can be administered to inhibit graft-
vs-host disease (GVHD) while preserving graft-vs-leukemia activity after allogeneic bone
marrow transplantation in mice. Preclinical studies suggest that it is necessary to infuse as
many Tregs as conventional donor T cells to achieve a clinical effect on GVHD. Thus, it
would be necessary to expand Tregs ex vivo before transplantation. Two strategies have
been proposed: expansion of Tregs stimulated by anti-CD3/CD28-coated microbeads for …
Abstract
CD4+ CD25+ immunoregulatory T cells (Tregs) can be administered to inhibit graft-vs-host disease (GVHD) while preserving graft-vs-leukemia activity after allogeneic bone marrow transplantation in mice. Preclinical studies suggest that it is necessary to infuse as many Tregs as conventional donor T cells to achieve a clinical effect on GVHD. Thus, it would be necessary to expand Tregs ex vivo before transplantation. Two strategies have been proposed: expansion of Tregs stimulated by anti-CD3/CD28-coated microbeads for polyclonal activation or by host-type allogeneic APCs for selecting Tregs specific for host Ags. In this study, we describe the mechanisms by which ex vivo-expanded Tregs act on donor T cells to prevent GVHD in mice. We demonstrate that expanded Tregs strongly inhibited the division, expansion, and differentiation of donor T cells, with a more pronounced effect with Tregs specific for host Ags. These latter cells permit the efficient and durable control of GVHD and favor immune reconstitution.
journals.aai.org